U-SRNE

Q:SRNE - SORRENTO THERAPEUTICS INC - http://www.sorrentotherapeutics.com

19:05:52 EDT

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
SRNE - Q	0.1	2.50	·	2.53	1.0	2.52	-0.23	-8.4	10,109.2	24,799	9,861	2.67 2.72 2.47	9.63 1.15	18:38:32	09:00	15 min RT 2¢

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market: Nasdaq -- Bid Tick: Down -- UPC Restricted: No

Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 2 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · 1yr Bulletins · Historical · Options · Portfolio

Recent Trades - Last 10 of 9861

Time ET	Ex	Price	Change	Volume
18:38:32	Q	2.50	-0.25	30
18:34:30	Q	2.52	-0.23	5
18:34:03	Q	2.52	-0.23	1
18:33:52	Q	2.52	-0.23	1
18:21:50	Q	2.52	-0.23	1
18:08:58	Q	2.51	-0.24	150
18:04:47	Q	2.52	-0.23	1
18:04:31	Q	2.52	-0.23	1
17:58:55	Q	2.53	-0.22	1
17:54:13	Q	2.53	-0.22	180

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Date ET	Symbol	Type	Headline
2022-08-16 09:00	U:SRNE	News Release200	Scilex Holding Company, a Sorrento Company, Announces Expanding Coverage to 30 Million Lives And Will Continue To Work To Access An Additional 20 Million Lives With One Of The Largest National Pharmacy Benefit Managers (PBMs) For ZTlido(TM) (lidocaine top
2022-08-03 09:00	U:SRNE	News Release200	Sorrento Completes Successfully the SAD Study and Initiates the MAD Phase 1 Study with STI-1558, An Oral M(pro) Inhibitor as a Standalone Treatment and Prevention of COVID-19 without the Ritonavir as Booster

Date ET

Symbol

Type

Headline

2022-08-16 09:00

U:SRNE

News Release

Scilex Holding Company, a Sorrento Company, Announces Expanding Coverage to 30 Million Lives And Will Continue To Work To Access An Additional 20 Million Lives With One Of The Largest National Pharmacy Benefit Managers (PBMs) For ZTlido(TM) (lidocaine top

2022-08-03 09:00

U:SRNE

News Release

Sorrento Completes Successfully the SAD Study and Initiates the MAD Phase 1 Study with STI-1558, An Oral M(pro) Inhibitor as a Standalone Treatment and Prevention of COVID-19 without the Ritonavir as Booster